Medication safety with oral antitumour therapeutics in paediatrics (youngAMBORA): A mixed-methods approach towards a

Phyllis Lensker1,2,3,4, Lisa Cuba1,2,3, Katja Gessner2,3

  • 1Pharmacy Department, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

Plos One
|December 5, 2024
PubMed

Insights

A new pediatric care program, youngAMBORA, was developed to address challenges with oral antitumour therapeutics (OAT) in children. This program focuses on medication education, application support, and side effect evaluation, improving safety and outcomes for young cancer patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Pediatrics

Background:

  • Oral antitumour therapeutics (OAT) offer improved outcomes and convenience but present complex intake challenges.
  • Existing clinical pharmacological/pharmaceutical care programs for OAT have shown success in adults (AMBORA trial).
  • Comparable care programs are lacking for pediatric patients receiving OAT.

Purpose of the Study:

  • To develop a tailored pharmacological/pharmaceutical care program for pediatric patients receiving OAT (youngAMBORA).
  • To identify specific demands and educational needs related to OAT in children.
  • To enhance medication safety and treatment adherence in pediatric oncology.

Main Methods:

  • A parallel mixed-methods approach was employed.
  • Quantitative analysis of tumor entities and OAT used in a pediatric cancer center.
  • Qualitative survey of patients, caregivers, and healthcare professionals to assess needs and challenges.

Main Results:

  • Leukemia and antimetabolites were the most frequent diagnoses and OAT, respectively.
  • 81.8% of pediatric patients desired involvement in oral medication education.
  • Healthcare professionals identified 'Smell/taste', 'Refusal of intake', and 'Swallowing problems' as more challenging application issues compared to caregivers.
  • Two novel side effects ('Skin dryness', 'Taste changes') were identified, not present in the CTCAE library.

Conclusions:

  • The youngAMBORA program will incorporate counseling for OAT, child-friendly application support, and systematic side effect evaluation.
  • The program will address 17 relevant side effects from patient and caregiver perspectives.
  • Age-appropriate information materials will be developed to support pediatric patients and caregivers.
Abstract

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
39
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
773
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K